Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-02-23
2009-12-29
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000
Reexamination Certificate
active
07638501
ABSTRACT:
In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such as triacetyluridine, or the like. Also provided are methods of reducing or eliminating symptoms associated with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment include those attributable to a deficiency of one or more pyrimidines.
REFERENCES:
patent: 4960759 (1990-10-01), De Luca et al.
patent: 5190948 (1993-03-01), Materazzi et al.
patent: 5470838 (1995-11-01), von Borstel et al.
patent: 5567689 (1996-10-01), Sommadossi et al.
patent: 5583117 (1996-12-01), von Borstel et al.
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 5723449 (1998-03-01), Sommadossi et al.
patent: 5736531 (1998-04-01), von Borstel et al.
patent: 5852000 (1998-12-01), Ichihara et al.
patent: 5962459 (1999-10-01), Piazza et al.
patent: 5968914 (1999-10-01), von Borstel et al.
patent: 5981601 (1999-11-01), Nagley et al.
patent: 6020320 (2000-02-01), von Borstel et al.
patent: 6020322 (2000-02-01), von Borstel et al.
patent: 6054441 (2000-04-01), von Borstel et al.
patent: 6232298 (2001-05-01), von Borstel et al.
patent: 6258795 (2001-07-01), von Borstel et al.
patent: 6274563 (2001-08-01), von Borstel et al.
patent: 6297222 (2001-10-01), von Borstel et al.
patent: 6306834 (2001-10-01), von Borstel et al.
patent: 6316426 (2001-11-01), von Borstel et al.
patent: 6329350 (2001-12-01), von Borstel et al.
patent: 6344447 (2002-02-01), von Borstel et al.
patent: 6348451 (2002-02-01), von Borstel et al.
patent: 6472378 (2002-10-01), VonBorstel
patent: 6743782 (2004-06-01), von Borstel et al.
patent: 2001/0005719 (2001-06-01), von Borstel
patent: 2001/0016576 (2001-08-01), von Borstel
patent: 2002/0049182 (2002-04-01), Von Borstel et al.
patent: 53056690 (1978-05-01), None
patent: WO 89/03837 (1989-05-01), None
patent: WO 00/11952 (2000-03-01), None
patent: WO 00/50043 (2000-08-01), None
website: www.ctnow.com, William Hathaway, The Hartford Courant, Apr. 10, 2001.
Elverland et al., American Journal of Otology, (Nov. 1991), 12/6, pp. 45-465 (abstract).
Schorlemmer et al., International Journal of Immunotherapy, (1999) 14(4), pp. 193-204 (abstract).
The Merck Index, 17thedition (1999), pp. 157-161.
North et al., Journal of Virology, 1981, p. 987-993.
Ashour, O.M. et al., “5-(m-Benzyloxybenzyl) Barbituric Acid Acyclonucleoside, A Uridine Phosphorylase Inhibitor, and 2′, 3′, 5′-tri-O-Acetyluridine, A Prodrug of Uridine, As Modulators of Plasma Uridine Concentration. Implicaitons for Chemotherapy.”Biochem Pharmacol., vol. 51, No. 12, Jun. 1996, pp. 1601-1611, (Abstract).
Bjornberg, O. et al., “The Activity ofEscherichia coliDihydroorotate Dehydrogenase Is Dependent On a Conserved Loop Identified By Sequence Homolgy, Mutagenesis, and Limited Proteolysis,”Biochemistry, vol. 38, No. 10, Mar. 9, 1999, (Abstract) pp. 2899-2908.
Bruneau, J.M. et al., “Purification of Human Dihydro-Orotate Dehydrogenase and Its Inhibition by a A77 1726, the Active Metabolite of Leflunomide,”Biochem. J., vol. 336, Part 2, Dec. 1, 1998, (Abstract) pp. 299-303.
Chariot, P. et al., “Zidovudine-Induced Mitochondrial Disorder with Massive Liver Steatosis, Myopathy, Lactic Acidosis, and Mitochondrial DNA Depletion,”J. Hepatol., vol. 30, No. 1, Jan. 1999, (Abstract) pp. 156-160.
Cheong H.I. et al., “Hereditary Glomerulopathy Associated With A Mitochondrial tRNA (Leu) Gene Mutation,”Pediatr. Nephrol., vol. 13, No. 6, Aug. 1999, (Abstract) pp. 477-480.
Connolly, Gerald P., “Abnormal Pyrimidine Metabolism Is the Basis of Some Neurological Diseases,”Trends Pharmacol. Sci., vol. 19, No. 7, Jul. 1998, p. 252.
Connolly, Gerald P. et al., “Pyrimidines and CNS Regulation,” and “McLeod et al. Reply”.TIPS, vol. 17, No. 1, Mar. 1996, pp. 106-107.
Connolly and Duley, “Uridine and Its Nucleotides: Biological Actions, Therapeutic potentials,”TIPS, vol. 20, May 1999, pp. 218-225.
Costanzi-Strauss, E. et al., “Restoration of Growth Arrest By a p16INK4, p21WAF1, pRB, and p53 is Dependent on the Integrity of the Endogenous Cell-Cycle Control Pathways in Human Glioblastoma Cell Lines,”Exp. Cell Res., vol. 238, No. 1, Jan. 10, 1998, (Abstract) pp. 51-62.
Damore, M.E. et al., “Early Onset of Diabetes Mellitus Associated With the Mitochondrial DNA T14709C Point Mutation: Patient Report and Literature Review,”J. Pediatr. Endocrinol. Metab., vol. 12, No. 2, Mar.-Apr. 1999, (Abstract) pp. 207-213.
De la Asuncion, J.G. et al., “AZT Treatment Induces Molecular and Ultrastructural Oxidative Damage to Muscle Mitochondria. Prevention By Antioxidant Vitamins,”J. Clin. Invest., vol. 102, No. 1, Jul. 1998, (Abstract) pp. 4-9.
De Muys, J.M. et al., “Anti-Human Immunodeficiency Virus Type 1 Activity, Intracellular Metabolism, and Pharmacokinetic Evaluation of 2′-deoxy -3′-oxa-4′-thiocytidine,”Antimicrob. Agents Chemother., vol. 43, No. 8, Aug. 1999, (Abstract) pp. 1835-1844.
Fox, R.I., “Mechanism of Action of Leflunomide in Rheumatoid Arthritis,”J. Rheumatol. Suppl., vol. 53, Jul. 1998, (Abstract) pp. 20-26.
Graff, C. et al., “Mitochondrial Medicine—Recent Advances,”J. Intern. Med., vol. 246, No. 1, Jul. 1999, (Abstract) pp. 11-23.
Gregoire, Michel et al., “On Auxotrophy for Pyrimidines of Respiration-Deficient Chick Embryo Cells,”Euro. J. Biochem., vol. 142, 1984, pp. 49-55.
Janssen, G.M. et al., “The Diabetes-Associated 3243 Mutation In the Mitochondrial tRNA (Leu(UUR)) Gene Causes Severe Mitochondrial Dysfunction Without A Strong Decrease In Protein Synthesis Rate,”J. Biol. Chem., vol. 274, No. 42, Oct. 15, 1999, (Abstract) pp. 29744-29748.
Jockel, J. et al., “Structural and Functional Comparison of Agents Interfering with Dihydroorotate, Succinate and NADH Oxidation of Rat Liver Mitochondria,”Biochem. Pharmacol., vol. 56, No. 8, Oct. 15, 1998, (Abstract) pp. 1053-1060.
Kelsen, David P. et al., “Phase I Trial of PN401, an Oral Prodrug of Uridine, to Prevent Toxicity From Fluorouracil in Patients with Advanced Cancer,”Journal of Clinical Oncology, vol. 15, No. 4, Apr. 1997, pp. 1511-1517.
Knecht and Loffler, “Species-Related Inhibition of Human and Rat Dihydroorotate Dehydrogenase By Immunosuppressive Isoxazol and Chinchoninic Acid Deriviative,”Biochem. Pharmacol., vol. 56, No. 9, Nov. 1998, (Abstract) pp. 1259-1264.
Kraft, J. et al., “Biological Effects of the Dihydroorotate Dehydrogenase Inhibitor Polyporic Acid, A Toxic Constituent of the MushroomHapalopilus rutilans, In Rats and Humans,”Arch. Toxicol., vol. 72, No. 11, Nov. 1998, (Abstract) pp. 711-721.
Lehto, M. et al., “High Frequency of Mutations In MODY and Mitochondrial Genes In Scandinavian Patients With Familial Early-Onset Diabetes,”Diabetologia, vol. 42, No. 9, Sep. 1999, (Abstract) pp. 1131-1137.
Loffler, M. et al., “Dihydroorotat-Ubiquinone Oxidoreductase Links Mitochondria In the Biosynthesis of Pyrimidine Nucleotides,”Mol. Cell Biochem., vol. 174., 1997, pp. 125-129.
Masanes, F. et al. “Clinical, Histological and Molecular Reversibility of Zidovudine Myopathy;”J. Neurol. Sci., vol. 159, No. 2, Aug. 14, 1998, (Abstract) pp. 226-228.
Masini, A. et al., “Zidovudine-Induced Experimental Myopathy: Dual Mechanism of Mitochondrial Damage,”J. Neurol. Sci., vol. 1666, No. 2, Jul. 1, 1999, (Abstract) pp. 131-140.
Matsuura, N. et al., “The prevalence of Mitochondrial Gene Mutations In Childhood Diabetes In Japan,”J. Pediatr. Endocrinol. Metab., vol. 12, No. 1, Jan.-Feb. 1999, (Abstract) pp. 27-30.
Morris, A.A., “Mitochondrial Respiratory Chain Disorders and the Liver,”Liver, vol. 19, No. 5, Oct. 1999, (Abstract) pp. 357-368.
Nakamura S. et al., “Renal Complic
DLA Piper (LLP) US
Kwon Brian-Yong S
The Regents of the University of California
LandOfFree
Method of treatment of mitochondrial disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of mitochondrial disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of mitochondrial disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4146412